PABA
Best-in-class: PABA
A B-complex-associated compound used for skin, hair pigmentation and connective-tissue/fibrosis support (Peyronie's, scleroderma).
PABA quick facts
| Suggested dose | As directed. |
| How often | Daily |
| Who it's for | Skin/connective-tissue and hair-pigmentation support (niche). |
The honest summary is that the oral evidence is old, small and weak, and the historical topical use was abandoned because it stained clothing and caused contact allergy. It also directly antagonizes sulfonamide antibiotics, which is a real interaction. Listed for completeness rather than as something most people should be taking.
How PABA actually works
Para-aminobenzoic acid is a structural component of folate in bacteria — which is what sulfonamide antibiotics exploit, competing with it to block bacterial folate synthesis. Humans cannot make folate from it, so PABA is not a vitamin for us despite historically being grouped with the B complex. It was an early topical UV filter, absorbing UVB directly, and has been investigated orally in fibrotic skin conditions with an unclear mechanism.
Where to get PABA
Find PABA on iHerb →The evidence for PABA
Graded by what exists behind each claim.
✅ Clinically validated
- Studied for skin-fibrosis conditions (Peyronie's, scleroderma) and premature graying; folate-related roles.
- Supports fibroblast/connective-tissue function.
📊 Correlative data
- Widely used as a sunscreen ingredient until contact allergy and photosensitivity in the population led to its removal from most formulations. That is the main observational record; oral use has almost none.
🧪 Theoretical / extrapolated benefits
- Niche uses; broad benefit claims are weak.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What PABA actually does
Para-aminobenzoic acid is not a human vitamin. It has been sold beside the B complex since the 1940s, when anything that a microorganism needed for growth was liable to be given a B number, and the name stuck after the biochemistry had moved on. Humans have no requirement, no deficiency syndrome and no enzyme that uses it. Saying that first is not a rhetorical move; it is the fact that organizes everything below.
The enzyme PABA is a substrate for is bacterial, and it is the enzyme sulfa drugs block. Dihydropteroate synthase — the folP gene product — condenses para-aminobenzoic acid with 6-hydroxymethyl-7,8-dihydropterin pyrophosphate to build the pteroate backbone of folate. Bacteria have to make folate from scratch because they cannot import it; we do not, because we eat it and carry a reduced folate carrier and a proton-coupled folate transporter to bring it in whole. Sulfonamides are structural analogs of PABA: they occupy the same site on dihydropteroate synthase and the bacterium starves of folate. That is the entire basis of a class of antibiotics, and it is why swallowing PABA and swallowing a sulfa drug at the same time is pharmacological antagonism by design rather than by accident — the supplement is the natural substrate the drug was shaped to imitate Office of Dietary Supplements.
What happens to it in a person, and it is unusually well defined. Oral PABA is absorbed rapidly and almost completely, then handled by two conjugation routes: N-acetylation by N-acetyltransferase to p-acetamidobenzoic acid, and glycine conjugation to p-aminohippurate. Recovery in urine is so nearly complete and so fast that PABA is used clinically for something else entirely — as a marker to validate 24-hour urine collections, because a collection that recovers less than about 85% of a swallowed PABA tablet was incomplete. That is a checkable, load-bearing fact about this molecule: it is used in medicine as a tracer precisely because it does nothing and leaves promptly.
The folate connection people assume, and why it does not work. PABA is a folate precursor for organisms that possess dihydropteroate synthase. A human liver cannot condense it into anything; the human folate problem is at the other end of the pathway, where dihydrofolate reductase reduces folic acid slowly and variably Bailey 2009 and where the methyl cycle needs 5-methyl-tetrahydrofolate rather than a pteroate precursor Samaniego-Vaesken 2024. If your folate status is poor, PABA cannot help. The one place it plausibly could matter is your colonic bacteria, which do make folate and do use PABA — and that is an experiment nobody has run.
The fibrosis hypothesis, stated as the hypothesis it is. Potassium para-aminobenzoate was introduced for Peyronie's disease and scleroderma on the proposal that it raises tissue oxygen uptake and increases monoamine oxidase activity, reducing serotonin-driven fibrogenesis and glycosaminoglycan deposition in connective tissue. That proposal is from the 1950s. It has never been confirmed in a modern mechanistic study, there is no identified receptor or enzyme target in human fibroblasts, and the honest description is that the drug arrived before the mechanism and the mechanism never caught up.
Cell, rodent, human — and where it stops
In cells: essentially nothing usable. There is no modern cell-culture literature establishing an effect of PABA on human fibroblast collagen synthesis, transforming growth factor beta signaling, or any other target the fibrosis claim would need. This is not an oversight in the search; it is the state of the field.
In rodents: also essentially nothing. No animal model of Peyronie's plaque or scleroderma has been used to test PABA in a way that would support the human dosing. The molecule skipped the preclinical stage because it entered clinical use before that stage was standard.
In people, once, properly. A prospective, placebo-controlled, randomized study of potassium para-aminobenzoate in Peyronie's disease, run in Germany over twelve months at 3 g four times daily — 12 g a day — found a reduction in plaque size and a reduced likelihood of the deformity getting worse, without a significant change in existing penile curvature Weidner 2005. That is a real randomized trial with a real result and it is the only one of its kind. Everything else in the human PABA literature is case series, uncontrolled reports from the 1940s and 1950s, or narrative.
The specific obstacle is a factor of twenty-four, and it is arithmetic rather than opinion. The trial dose was 12 g a day, taken as four separate 3 g doses, for a year Weidner 2005. The filed label of the product a reader is likely to buy declares 500 mg per capsule, one capsule daily Office of Dietary Supplements. Nobody has ever tested 500 mg of PABA against any endpoint at all, and there is no dose-response curve in this literature from which to interpolate. A reader taking the shelf dose is not taking a smaller version of the trial; they are off the bottom of the only chart that exists.
Two claims with no controlled human evidence whatsoever. Hair repigmentation traces to uncontrolled 1940s reports in which PABA was given alongside other B vitamins to small numbers of people and gray hair was said to darken; there has never been a randomized trial, and gray hair does not spontaneously repigment, so an uncontrolled observation of darkening is exactly the kind of result that needs a control group. Scleroderma has the same status: decades of use, no modern randomized evidence.
PABA — which form, and does it matter
Three different substances share this name and they are not interchangeable. Potassium para-aminobenzoate, the potassium salt sold as a prescription-grade product, is the form in the Peyronie's trial and in the hepatitis report Weidner 2005Roy 2008. PABA free acid is what a dietary supplement capsule contains Office of Dietary Supplements. And para-aminobenzoic acid as a topical ultraviolet-B filter, which is what most people over fifty actually met it as, is a third exposure entirely — on the skin, not swallowed.
The salt is not a trivial difference at these doses. Twelve grams a day of the potassium salt carries a substantial potassium load with it, taken in four divided doses with food and fluid because the gastrointestinal tolerance of the free acid at that quantity is poor. A reader who decided to reproduce the trial with 24 capsules of a 500 mg free-acid supplement would be running a different experiment with a different tolerability profile and no supervision.
The sunscreen history is worth getting right, because it is the only part of PABA's record that is genuinely population-scale. PABA and its esters were among the first effective UVB filters and were removed from most sunscreen formulations after contact and photocontact allergy proved common enough to matter. That is a topical sensitization story. It says something about how the immune system meets this molecule in skin and it says nothing about whether swallowing 500 mg does anything — but it is also why a person with a known PABA allergy is warned off the oral product on the label Office of Dietary Supplements.
What the site's own card gets right and what it does not. The card's honesty about weak evidence is correct and unusual. What no card states is the dose gap: naming Peyronie's and scleroderma as the studied uses while the product is dosed at one twenty-fourth of the studied dose lets a reader assume a connection between the two that the numbers do not support.
What would have to be true, and how you would know it was not
1. A urinary recovery test, which is the one pharmacological prediction this molecule reliably makes. Take a single 500 mg dose and collect urine for 24 hours. Predict that essentially all of it comes back as PABA plus its acetyl and glycine conjugates within that window. That is why laboratories use PABA to check whether a 24-hour collection was complete. The point of running it here is not the number but what the number means: a compound that is absorbed, conjugated and excreted within a day is not accumulating anywhere and is not building a tissue reservoir, so any claim about slow structural change has to be a claim about repeated daily exposure over months.
2. ALT and AST at eight weeks if you take more than 4 g a day. Drug-induced liver injury is the one documented serious adverse event on this molecule Roy 2008, and transaminases are the cheapest way to see it coming. Predict no change at 500 mg. Predict that anybody taking gram quantities without checking is running the only real risk this product carries and is running it blind.
3. The prediction that cuts against the product, stated in advance so it cannot be reinterpreted afterwards: at 500 mg a day, predict nothing. No change in plaque, no change in curvature, no change in skin texture, no change in hair color. The only positive randomized result on this molecule is at 12 g a day for a year Weidner 2005, and a dose twenty-four times smaller has no evidential claim on that result. If you are taking PABA for Peyronie's disease, the honest options are the studied dose under urological supervision or a different treatment.
4. A negative control you can run in a week. If you are also prescribed a sulfonamide antibiotic — trimethoprim-sulfamethoxazole is the common one — predict that taking PABA alongside it reduces the antibiotic's effect, because the supplement is the substrate the drug competes with at dihydropteroate synthase Office of Dietary Supplements. This is the one prediction on the page you should not test. It is here because it is the mechanism, and because the label's own warning is not decoration.
What will fool you: the company it keeps. PABA is usually swallowed inside a B-complex, so a person who feels better on it has changed their B6, B12, folate and riboflavin intake at the same time. Any effect worth attributing to PABA has to be observed with PABA alone.
What nobody has tested yet
Nobody has tested the shelf dose against anything. There is no trial, of any design, of 500 mg of PABA daily for any indication Office of Dietary Supplements. A twelve-week randomized trial at 500 mg, 2 g and placebo with a defined endpoint would either give this product its first evidence or establish that the shelf dose is inert. It has never been run in eighty years of sale.
Nobody has repeated the Peyronie's trial with modern measurement. The randomized result used plaque size and deterioration as endpoints Weidner 2005. A repeat with photographic goniometry of curvature, ultrasound plaque volume and a validated patient-reported outcome would settle whether the effect is real and clinically meaningful, and it would take one urology department a year.
Nobody has measured what PABA does to the human gut microbiome's folate synthesis. This is the most interesting unrun experiment on the page and it follows directly from the mechanism: colonic bacteria possess dihydropteroate synthase, PABA is its substrate, and a large oral dose delivers substrate to that compartment. Measure fecal folate, microbial composition and host serum folate before and after four weeks at 500 mg. It is plausible that the only real biology of oral PABA in a human happens in the colon and belongs to somebody else's cells. That prediction is labeled extrapolation, and it is testable this year.
And nobody has established a mechanism for the fibrosis claim. Seventy years after the monoamine oxidase and tissue-oxygen proposal, there is still no identified target in a human fibroblast. A single well-designed cell experiment — PABA against dermal fibroblasts with collagen I, transforming growth factor beta signaling and glycosaminoglycan output as read-outs — would be the first modern mechanistic data this molecule has ever had.
PABA — its own safety story, not its category's
The liver, and this is not a theoretical caution. Acute hepatitis has been reported in a patient treated with potassium para-aminobenzoate for Peyronie's disease Roy 2008, and the pattern in the wider literature is the same — hepatic injury and hematological reactions clustered at the gram-per-day doses used for fibrosis, not at nutritional doses. The manufacturer's own supplement label carries the corresponding instruction to consult a physician in liver or renal disease Office of Dietary Supplements. If you are taking this at the studied dose, you are taking a drug and should be monitored like somebody taking a drug.
The sulfonamide antagonism is the interaction that is genuinely specific to this molecule. Almost every supplement page warns about interactions in the abstract; this one has a competitive-inhibition mechanism with the direction known. PABA is the natural substrate of the enzyme sulfa antibiotics inhibit, so supplemental PABA works against the drug. The label states it as a contraindication rather than a caution Office of Dietary Supplements, and that is the correct strength of wording.
Hypoglycemia, which is on the drug labeling and off most supplement pages. Low blood glucose has been reported with high-dose para-aminobenzoate, and it is one reason the four-times-daily regimen in the trial specified dosing with food and fluid Weidner 2005. Anybody taking insulin or a sulfonylurea alongside gram doses has a reason to check.
Allergy, and it arrives from the skin. A person sensitized to PABA by decades-old sunscreens can react to the oral form, and the label names known PABA allergy as a reason not to take it Office of Dietary Supplements. Cross-reactivity with other para-amino compounds — some local anesthetics, some hair dyes — is the reason this matters more than it sounds.
The honest bottom line for the shelf dose. At 500 mg a day, the realistic profile is nausea, appetite loss and rash at the unpleasant end and nothing at all at the likely end. The risk is small because the dose is small; the benefit is unmeasured for exactly the same reason. This page's view is that PABA is a molecule with one real clinical use, at a dose nobody sells, and that a reader is better served by knowing that than by a paragraph of encouragement.
Sources read for this page
- Weidner W, et al. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. European Urology 2005 · PMID 15774254
- Roy J, et al. Acute hepatitis associated with treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). Journal of Sexual Medicine 2008 · PMID 18624965
- Office of Dietary Supplements, National Institutes of Health. PABA 500 mg (NOW) -- filed Supplement Facts panel: PABA 500 mg per capsule, one capsule daily with food; label warning that PABA should not be taken when using sulfonamide drugs or in known PABA allergy, and to consult a physician in liver or renal disease; on market. NIH Dietary Supplement Label Database, DSLD ID 313894
- Bailey SW, et al. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proceedings of the National Academy of Sciences 2009 · PMID 19706381
- Samaniego-Vaesken ML, et al. Supplementation with Folic Acid or 5-Methyltetrahydrofolate and Prevention of Neural Tube Defects: An Evidence-Based Narrative Review. Nutrients 2024 · PMID 39339754
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: New hair at the root, photographed monthly at the same parted spot under the same light. Only new growth can come in a different color — nothing already on your head will change — so the root is the only place a pigmentation claim can be scored at all, and the first month cannot show you anything. New growth arrives at roughly 10 mm a month, so photograph the same spot every 30 days.
- How long before it means anything: 6 months at minimum, because you are waiting for enough new length to judge. That is about 60 mm of new growth to compare against. Anything shorter is looking at hair that had already grown before the first capsule.
- What will fool you: There is no controlled trial behind the graying claim, so you are scoring a story against a photograph, and gray hair does not repigment spontaneously — which means most impressions of improvement are lighting. The fibrosis uses, Peyronie's and scleroderma, are specialist conditions rather than self-treated ones. And PABA interferes with sulfa antibiotics, so anyone who might be prescribed one has a concrete reason to mention it. Its own history is the footnote worth keeping: it was a sunscreen ingredient until contact allergy and photosensitivity took it out of most formulations.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
PABA — safety & side effects
- Nausea, rash and loss of appetite. Higher doses are poorly tolerated.
- Liver toxicity and blood disorders have been reported at doses above 8 g/day, and fever and rash are recognized hypersensitivity reactions.
- Antagonizes sulfonamide antibiotics — it is the molecule they compete with, so it directly reduces their effectiveness. Avoid if you are on one.
- Little evidence of benefit for the uses it is sold for. Not one we would reach for.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — PABA in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside PABA
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Vitamin D (25-Hydroxy) | The one most often actually low, and the one with a real ceiling |
| Vitamin B12 | Commonly low in older adults, vegetarians and metformin users |
| Folate, Serum | Read alongside B12 — supplementing one can mask the other |
| Homocysteine | The functional read on whether your B vitamins are working |
The Full Micronutrient Screen panel covers these in one order — 11 markers, $363.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
PABA — frequently asked questions
What is PABA?
A B-complex-associated compound used for skin, hair pigmentation and connective-tissue/fibrosis support (Peyronie's, scleroderma).
What is the suggested dose of PABA?
As directed. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find PABA dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy PABA?
Coach Cam sources PABA from vetted, top-rated brands on iHerb — use the buy link on this page.
What PABA is used for
PABA appears under 2 goals in the goal router.
Related Vitamins supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.